13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001858703
Total reported value
$664.5M
$664.5M
41 檔
23.7%
According to the latest 13F quarterly dataset, Blue Owl Capital Holdings LP managed an equity portfolio of $664.5M at the end of Q2 2024, spanning 41 distinct U.S. exchange-listed positions.
In Q2 2024, Blue Owl Capital Holdings LP adopted a defensive or profit-taking posture, trimming 8 positions and completely liquidating 15 holdings to manage risk exposure.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | CGEM | Cullinan Therapeutics Inc | Stock-Other | 9.95% | -3.07% | -29.94% | |
| 2 | PLRX | Pliant Therapeutics Inc | Stock-Other | 9.00% | -1.01% | EXIT | |
| 3 | OBDC | Blue Owl Capital CORP | Stock-Financials | 8.75% | -2.73% | — | |
| 4 | KVYO | Klaviyo Inc-a | Stock-Other | 8.31% | — | — | |
| 5 | LRMR | Larimar Therapeutics Inc | Stock-Other | 7.79% | -4.40% | -3.38% | |
| 6 | ✓ | Engene Holdings Inc | Stock-Other | 6.43% | -8.08% | EXIT | |
| 7 | TRML | Tourmaline Bio Inc | Stock-Other | 6.14% | — | +18.52% | |
| 8 | EVCM | Evercommerce Inc | Stock-Other | 5.02% | — | — | |
| 9 | ✓ | Acelyrin Inc | Stock-Other | 3.59% | — | +3.54% | |
| 10 | RPTX | Repare Therapeutics Inc | Stock-Other | 3.10% | — | +8.01% | |
| 11 | RARE | Ultragenyx Pharmaceutical In | Stock-Other | 3.07% | -0.78% | — | |
| 12 | CNTX | Context Therapeutics Inc | Stock-Other | 2.88% | -3.34% | — | |
| 13 | IRON | Disc Medicine Inc | Stock-Other | 2.70% | — | +38.64% | |
| 14 | TOST | Toast Inc-class A | Stock-Tech | 2.32% | — | — | |
| 15 | ETWOGBP | E2open Parent Holdings Inc | Stock-Other | 2.06% | — | — | |
| 16 | KROS | Keros Therapeutics Inc | Stock-Other | 2.01% | — | -8.69% | |
| 17 | ✓ | Ikena Oncology Inc | Stock-Other | 1.88% | — | +5.14% | |
| 18 | SGMT | Sagimet Biosciences Inc-a | Stock-Other | 1.59% | +1.00% | — | |
| 19 | MLYS | Mineralys Therapeutics Inc | Stock-Other | 1.47% | — | -16.77% | |
| 20 | VKTX | Viking Therapeutics Inc | Stock-Healthcare | 1.40% | — | — | |
| 21 | ✓ | Inozyme Pharma Inc | Stock-Other | 1.39% | — | -11.81% | |
| 22 | STWD | Starwood Property Trust Inc | Stock-Real Estate | 1.19% | -0.25% | — | |
| 23 | PYXS | Pyxis Oncology Inc | Stock-Other | 0.96% | — | — | |
| 24 | MREO | Mereo Biopharma Group Pl-adr | Stock-Other | 0.90% | — | — | |
| 25 | AQST | Aquestive Therapeutics Inc | Stock-Other | 0.83% | -0.91% | +30.29% | |
| 26 | CMPX | Compass Therapeutics Inc | Stock-Other | 0.79% | -2.99% | — | |
| 27 | ✓ | Adc Therapeutics SA | Stock-Other | 0.65% | -0.58% | — | |
| 28 | OHI | Omega Healthcare Investors, Inc. | Stock-Real Estate | 0.61% | — | — | |
| 29 | GPCR | Structure Therapeutics Inc | Stock-Other | 0.60% | — | — | |
| 30 | IMVT | Immunovant Inc | Stock-Other | 0.59% | — | -20.00% | |
| 31 | SYRS | Syros Pharmaceuticals Inc | Stock-Other | 0.49% | — | — | |
| 32 | JANX | Janux Therapeutics Inc | Stock-Other | 0.47% | — | — | |
| 33 | CELC | Celcuity Inc | Stock-Other | 0.30% | +0.02% | NEW | |
| 34 | BLND | Blend Labs Inc-a | Stock-Other | 0.24% | — | — | |
| 35 | GOCOQ | Gohealth Inc-class A | Stock-Other | 0.23% | -0.02% | EXIT | |
| 36 | PLMKW | Plum Acquisition Corp. IV | Stock-Other | 0.09% | — | — | |
| 37 | DM* | Desktop Metal Inc-a | Stock-Other | 0.09% | — | — | |
| 38 | DTIL | Precision Biosciences Inc | Stock-Other | 0.05% | — | — | |
| 39 | GERN | Geron CORP | Stock-Other | 0.03% | — | — | |
| 40 | ✓ | Engene Holdings Inc | Stock-Other | 0.02% | -0.35% | EXIT | |
| 41 | ✓ | Alpha Partners Technology Merg | Stock-Other | 0.01% | — | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | CNTX | Context Therapeutics Inc | +2.9% | NEW | New buy |
| 2 | KVYO | Klaviyo Inc-a | +2.2% | — | Unchanged |
| 3 | EVCM | Evercommerce Inc | +1.9% | — | Unchanged |
| 4 | LRMR | Larimar Therapeutics Inc | +1.7% | -3.38% | Trim |
| 5 | VKTX | Viking Therapeutics Inc | +1.4% | NEW | New buy |
| 6 | STWD | Starwood Property Trust Inc | +1.2% | NEW | New buy |
| 7 | PYXS | Pyxis Oncology Inc | +1% | NEW | New buy |
| 8 | MREO | Mereo Biopharma Group Pl-adr | +0.9% | NEW | New buy |
| 9 | ✓ | Ikena Oncology Inc | +0.8% | +5.14% | Add |
| 10 | TOST | Toast Inc-class A | +0.7% | — | Unchanged |
| 11 | GPCR | Structure Therapeutics Inc | +0.6% | NEW | New buy |
| 12 | ETWOGBP | E2open Parent Holdings Inc | +0.6% | — | Unchanged |
| 13 | RARE | Ultragenyx Pharmaceutical In | +0.6% | — | Unchanged |
| 14 | JANX | Janux Therapeutics Inc | +0.5% | NEW | New buy |
| 15 | CELC | Celcuity Inc | +0.3% | NEW | New buy |
| 16 | RPTX | Repare Therapeutics Inc | +0.2% | +8.01% | Add |
| 17 | PLMKW | Plum Acquisition Corp. IV | +0.1% | NEW | New buy |
| 18 | DM* | Desktop Metal Inc-a | +0.1% | NEW | New buy |
| 19 | AQST | Aquestive Therapeutics Inc | +0.1% | +30.29% | Add |
| 20 | MLYS | Mineralys Therapeutics Inc | +0.1% | -16.77% | Trim |
| 21 | PLRX | Pliant Therapeutics Inc | 0% | — | Unchanged |
| 22 | GERN | Geron CORP | 0% | NEW | New buy |
| 23 | BLND | Blend Labs Inc-a | 0% | — | Unchanged |
| 24 | CGEM | Cullinan Therapeutics Inc | 0% | -29.94% | Trim |
| 25 | ✓ | Adc Therapeutics SA | 0% | — | Unchanged |
| 26 | UBER | Uber Technologies Inc | 0% | EXIT | Sold out |
| 27 | ✓ | Fathom Digital Mfg CORP | -0.1% | EXIT | Sold out |
| 28 | IMVT | Immunovant Inc | -0.1% | -20.00% | Trim |
| 29 | ELVN | Enliven Therapeutics Inc | -0.1% | EXIT | Sold out |
| 30 | ✓ | Desktop Metal Inc Class A Comm | -0.1% | EXIT | Sold out |
| 31 | ✓ | Rallybio CORP | -0.1% | EXIT | Sold out |
| 32 | OHI | Omega Healthcare Investors, Inc. | -0.2% | — | Unchanged |
| 33 | ✓ | Acelyrin Inc | -0.2% | +3.54% | Add |
| 34 | SGMT | Sagimet Biosciences Inc-a | -0.2% | — | Unchanged |
| 35 | GTLB | Gitlab Inc-cl A | -0.2% | EXIT | Sold out |
| 36 | TRML | Tourmaline Bio Inc | -0.3% | +18.52% | Add |
| 37 | SNOW | Snowflake Inc | -0.3% | EXIT | Sold out |
| 38 | KROS | Keros Therapeutics Inc | -0.3% | -8.69% | Trim |
| 39 | CMPX | Compass Therapeutics Inc | -0.3% | — | Unchanged |
| 40 | ✓ | Engene Holdings Inc | -0.4% | -89.99% | Trim |
| 41 | BRZE | Braze Inc-a | -0.5% | EXIT | Sold out |
| 42 | OVID | Ovid Therapeutics Inc | -0.5% | EXIT | Sold out |
| 43 | ✓ | Inozyme Pharma Inc | -0.6% | -11.81% | Trim |
| 44 | BDTX | Black Diamond Therapeutics I | -0.7% | EXIT | Sold out |
| 45 | LABDUSD | Drx Dly S&p Biotech Bear 3x | -0.7% | EXIT | Sold out |
| 46 | MDGL | Madrigal Pharmaceuticals Inc | -0.7% | EXIT | Sold out |
| 47 | DELL | Dell Technologies -c | -0.9% | EXIT | Sold out |
| 48 | MLTX | Moonlake Immunotherapeutics | -1% | EXIT | Sold out |
| 49 | ✓ | Engene Holdings Inc | -1.9% | -0.47% | Trim |
| 50 | HOOD | Robinhood Markets Inc - A | -10.8% | EXIT | Sold out |
According to official SEC Form 13F filings, Blue Owl Capital Holdings LP reported a total U.S. public equity portfolio value of $664.5M across 41 disclosed positions in Q2 2024.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including CGEM, PLRX, OBDC) accounted for 23.7% of total reported equity market value during Q2 2024.
Top New Position Initiated
CNTX
市值: $10.3M
Top Position Liquidated / Trimmed
HOOD
前期市值: $54.0M
During Q2 2024, Blue Owl Capital Holdings LP's top holdings by market value included CGEM (9.9%)、PLRX (9.0%)、OBDC (8.8%). The largest single position, CGEM, represented 9.9% of total portfolio value.
In Q2 2024, Blue Owl Capital Holdings LP made 39 total portfolio adjustments, initiating 11 new buys, adding to 5 positions, trimming 8 holdings, and fully liquidating 15 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.